The lack of expected biomarkers to predict treatment response to anti-PD1 treatment was observed in the NCI-9742 nivolumab study for recurrent/metastatic NPC, where there was no statistical correlation with tumour PDL1 expression (155, 167). The gene discussed is CD274; the disease is neoplasm.